Charles S. Fuchs, Marwan Fakih, Lee Schwartzberg, Allen L. Cohn, Lorrin Yee, Luke Dreisbach, Mark F. Kozloff, Yong-jiang Hei, Francesco Galimi, Yang Pan, Vincent Haddad, Cheng-Pang Hsu, Antony Sabin and Leonard Saltz TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer Cancer 119
Version of Record online: 1 OCT 2013 | DOI: 10.1002/cncr.28353
In this phase 1b/randomized phase 2 trial of conatumumab with mFOLFOX6/bevacizumab for first-line treatment of metastatic colorectal cancer, conatumumab had a manageable toxicity profile but did not significantly improve progression-free survival or overall survival compared with placebo. These data do not support further development of conatumumab in advanced colorectal cancer.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field